Serum endocan levels in endometrial and ovarian cancers

Laloğlu, Esra; Kumtepe, Yakup; Aksoy, Hülya; Yılmaz, Emsal Pınar Topdağı

doi:10.1002/jcla.22079

Cited by 25 publications

(17 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in tissue or blood endocan level shows endothelial activation and neovascularization, which are indicators of inflammation and tumor progression [18]. Therefore, blood endocan level has been used as a biomarker for various cancers including ovarian or endometrial carcinoma, pre-eclampsia, and inflammation-related diseases such as cirrhosis, sepsis, hypertension, and Behcet's disease [18][19][20][21][22][23][24]. As well as presence and severity of inflammation-related diseases, these markers indicate cardiovascular and metabolic risk of patients [25].…”

Section: Biochemical Findingsmentioning

confidence: 99%

Does endocan level increase in women with polycystic ovary syndrome? A case — control study

2018

Self Cite

View full text Add to dashboard Cite

Objectives: To evaluate endocan levels of patients with polycystic ovary syndrome (PCOS) in comparison to healthy women. Material and methods: A cross-sectional case-control study on 88 patients with PCOS (mean age, 22.06 ± 4.24 years; body mass index [BMI], 23.9 ± 4.74 kg/m 2) and 87 age-and BMI-matched healthy women (mean age, 23.71 ± 4.42 years; BMI, 22.15 ± 3.03 kg/m 2). Results: Serum endocan level was significantly higher in PCOS group than control group (540.9 ± 280.3 pg/mL vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001). The presence of polycystic ovary finding on ultrasonography or oligomenorhea did not produce significant effect on serum endocan levels (p > 0.05). In PCOS group, endocan level was negatively correlated with BMI and C-reactive protein level, and positively correlated with high density lipoprotein level (p < 0.05). Conclusions: Blood endocan level is increased in PCOS. Further studies are needed to evaluate the clinical value of blood endocan level as a marker for the risk of cardiovascular and metabolic diseases in patients with PCOS.

show abstract

Section: Biochemical Findingsmentioning

confidence: 99%

Does endocan level increase in women with polycystic ovary syndrome? A case — control study

2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, ESM-1 plays a role in angiogenesis and inflammation. Numerous studies have demonstrated that ESM-1 can be used as a potential biomarker for detection in gastric cancer 36 , bladder cancer 37 , colorectal cancer 28 , hepatocellular carcinoma 38 , pituitary adenoma 39 , ovarian cancer 40 , breast cancer 41 , and acute leukemia 20 , but ESM-1 has not been investigated in OSCC.…”

Section: Discussionmentioning

confidence: 99%

Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression

et al. 2017

View full text Add to dashboard Cite

In Taiwan, oral cancer is the fourth most common cancer and the most common malignancy with a poor prognosis. Endothelial cell-specific molecule-1 (ESM-1) is secreted by vascular endothelial cells in the liver, lungs, kidneys, and gastrointestinal tract. ESM-1 expression is associated with tumor prognosis, metastasis, and angiogenesis in many cancers. However, few studies have examined the association of plasma ESM-1 levels with oral squamous cell carcinoma (OSCC) progression. We measured the plasma ESM-1 levels of 438 male OSCC patients through a commercial enzyme-linked immunosorbent assay. The Cancer Genome Atlas (TCGA) dataset was also used to analyze the ESM-1 levels in 328 OSCC patients and 33 normal tissues. Our results revealed that the plasma levels of ESM-1 in OSCC patients were significantly associated with the tumor (T) status but not with the lymph node status, metastasis, and cell differentiation. TCGA bioinformatics database analysis revealed that ESM-1 expression was significantly higher in OSCC patients than in normal individuals (p < 0.05). In addition, the examination revealed similar results for the ESM-1 expression levels and pathological stage in OSCC. In conclusion, plasma ESM-1 is a novel biomarker for predicting the T status in OSCC patients.

show abstract

“…In these studies, endocan levels in PCOS, as in other chronic diseases, were found to be higher than healthy control groups. 1,13,16,[18][19][20] Th e aim of this study is to compare the endocan level in PCOS patients with the healthy control group and to show the relationship between some cardiovascular risk indicators accompanying PCOS and endocan level.…”

Section: Introductionmentioning

confidence: 99%

Poli̇ki̇sti̇k Over Sendromunda (Pkos) Endotelyal Di̇sfonksi̇yonun Erken Serum Beli̇rteci̇: Endocan

Apaydın¹,

Demirci²,

Çakal³

2021

Sakarya Medical Journal

View full text Add to dashboard Cite

Objective Polycystic ovary syndrome (PCOS) is a common endocrinological disease in women of reproductive age and has a wide range of metabolic effects. Chronic low-grade inflammation and endothelial dysfunction plays a key role in the pathogenesis of PCOS and they are associated with an increased risk of cardiovascular disease. Endocan, is an inflammatory marker showing endothelial dysfunction. The aim of our study, to compare serum endocan levels in PCOS and healthy control groups and to determine the relationship between some cardiovascular risk factors and serum endocan levels. Materials and Methods This case-control study included 52 PCOS patients and 59 age-matched healthy controls. Patients were diagnosed as PCOS based on 2003 Rotterdam criteria. Demographic data, history of menstrual irregularity and infertility, polycystic ovary appearance in ultrasonography and hirsutism status were recorded. Endocan levels of PCOS patients and controls were compared. Data analysis was performed by using SPSS-22 for Windows (Statistical Package for Social Science, SPSS Inc. Chicago IL, USA®Z). Results The median (IQR) value of serum endocan level was 420.7 ng/L (355.2-570.3) in the PCOS group and 320.0 ng/L (219.9-455.9) in the control group (p=0.003). While there was no significant correlation between serum endocan and some cardiovascular risk factors such as waist circumference, hip circumference, BMI, LDL, triglyceride, systolic and diastolic arterial tension but a positive correlation was found between homeostatic model assessment insulin resistance (HOMA-IR) (r= 0.276, p= 0.003). Conclusion Serum endocan levels are higher in PCOS patients, in line with the literature. Endocan level shows a significant correlation with insulin resistance, one of the metabolic parameters. This may be a sign of early endothelial dysfunction in PCOS. Keywords endocan; endothelial dysfunction; polycystic ovary syndrome; inflammation Öz Amaç Polikistik over sendromu (PKOS), üreme çağındaki kadınlarda sık görülen endokrinolojik hastalıktır. PKOS'ta izlenen kronik düşük dereceli inflamasyon ve endotel disfonksiyon artmış kardiyovasküler hastalık riski ile ilişkilidir. Endocan, endotel disfonksiyonunu gösteren inflamatuar bir belirteçtir. Çalışmamızda PKOS ve sağlıklı kontrol grubunu serum endocan düzeyleri açısından karşılaştırmayı ve kardiyovasküler risk faktörleri ile serum endocan düzeyleri arasındaki ilişkiyi belirlemeyi amaçladık.

show abstract

Serum endocan levels in endometrial and ovarian cancers

Abstract: Although benign ovarian or endometrial disorders do not lead to expression of endocan, malignant cases can result in measurable endocan levels. This may be useful in differentiating benign and malign diseases of the endometrium or ovary.

Cited by 25 publications

References 41 publications

Does endocan level increase in women with polycystic ovary syndrome? A case — control study

Does endocan level increase in women with polycystic ovary syndrome? A case — control study

Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression

Poli̇ki̇sti̇k Over Sendromunda (Pkos) Endotelyal Di̇sfonksi̇yonun Erken Serum Beli̇rteci̇: Endocan

Contact Info

Product

Resources

About